1. Get the Diabetes Forum App for your phone - available on iOS and Android.
    Dismiss Notice
  2. Guest, we'd love to know what you think about the forum! Take the Diabetes Forum Survey 2021 »
    Dismiss Notice
  3. Diabetes Forum should not be used in an emergency and does not replace your healthcare professional relationship. Posts can be seen by the public.
    Dismiss Notice
  4. Guest, stay home, stay safe, save the NHS. Stay up to date with information about keeping yourself and people around you safe here and GOV.UK: Coronavirus (COVID-19). Think you have symptoms? NHS 111 service is available here.
    Dismiss Notice
Dismiss Notice
Find support, ask questions and share your experiences. Join the community »

Oral semaglutide outperforms empagliflozin in battle of diabetes tablets

Discussion in 'Diabetes News' started by DCUK NewsBot, Oct 25, 2019.

  1. DCUK NewsBot

    DCUK NewsBot · Well-Known Member

    Messages:
    4,059
    Likes Received:
    694
    Trophy Points:
    133
    Oral semaglutide, a tablet-based GLP-1 receptor agonist drug, has performed stronger in achieving weight loss and reduction in HbA1c than empagliflozin in a new trial. The results come from the PIONEER 2 clinical trial. The trial compared two different drug treatments in people with type 2 diabetes on metformin that had HbA1c levels of 53 mmol/mol (7.0%) and above. Oral semaglutide, marketed as Rybelsus, was recently approved for public use in the US by the Food and Drug Administration (FDA). Empagliflozin, marketed as Jardiance, is an SGLT2 inhibitor drug that was approved in the US in 2014. For people in the UK, empagliflozin is available on the NHS, but the newer drug oral semaglutide is not. The PIONEER 2 trial set out to measure the performance of the two drugs in reducing HbA1c and body weight. Participants were randomised to receive once-daily doses of either oral semaglutide (14mg dose) or empagliflozin (25mg dose). Both groups took these medications in addition to metformin. There were around four hundred participants in each group that completed the trial. Both treatments helped to reduce HbA1c but oral semaglutide demonstrated a stronger reduction. After 6 months, participants taking oral semaglutide reduced HbA1c by 15 mmol/mol (1.4%), compared to those taking empagliflozin which had an average reduction in HbA1c of 9 mmol/mol (0.9%). After 6 months, participants in both treatment groups had a similar level of weight loss. After 12 months, participants taking oral semaglutide showed greater weight loss, of 4.7kg versus 3.8kg in those taking empagliflozin. A greater number of participants in the semaglutide group (97%) completed the trial than those in the empagliflozin group (94%). Gastrointestinal adverse events were more common in the group taking oral semaglutide. The findings are published online, ahead of print, by the Diabetes Care journal.

    Continue reading...
     
    • Useful Useful x 1
  2. ickihun

    ickihun Type 2 · Master

    Messages:
    13,575
    Likes Received:
    18,441
    Trophy Points:
    298
    Side affects. Oh lord. Not for me.

    Maybe another med to interfere with metformin's good work. I wonder if any wish they hadn't disrupted their metformin.
     
  • Meet the Community

    Find support, connect with others, ask questions and share your experiences with people with diabetes, their carers and family.

    Did you know: 7 out of 10 people improve their understanding of diabetes within 6 months of being a Diabetes Forum member. Get the Diabetes Forum App and stay connected on iOS and Android

    Grab the app!
  • Tweet with us

  • Like us on Facebook